Levi A Garraway

This inventor holds 16 USPTO granted patents and 18 published patent applications, plus 2 CIPO patents and 11 EPO patents. Top assignees: Dana-Farber-Cancer Institute Inc., The Broad Institute, Inc., Massachusetts Institute of Technology. Active years: 2011-2026.

USPTO Granted Patents = 16 (Patent Applications = 18)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 11)

Average Co-Inventor Count = 2.8

ph-index = 2

Forward Citations = 67(Granted Patents)

Location History:

Newton, MA (US) (2011 - 2023)
Boston, MA (US) (2024)

Company Filing History:

16 out of 1,265

Dana-Farber-Cancer Institute Inc.

patents

5 out of 482

The Broad Institute, Inc.

patents

2 out of 8,576

Massachusetts Institute of Technology

Instituto Carlos Slim De La Salud, A.c.

patents

6. 1 out of 275

Massachusetts Eye and Ear Infirmary

The Brigham and Women's Hospital, Inc.

patents

9. 1 out of 1,959

University of Pittsburgh

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12522872 - METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY (2026-01-13),

2. 12146196 - C-RAF mutants that confer resistance to RAF inhibitors (2024-11-19),

3. 11963966 - Compositions and methods for treating ovarian tumors (2024-04-23),

4. 11789022 - MEK1 mutation conferring resistance to RAF and MEK inhibitors (2023-10-17),

5. 11788151 - C-RAF mutants that confer resistance to RAF inhibitors (2023-10-17),

6. 11186874 - ERK1 and ERK2 mutations that confer resistance to MAPK pathway inhibitors (2021-11-30),

7. 11078540 - Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy (2021-08-03),

8. 10968484 - Methods of identifying responses to map kinase inhibition therapy (2021-04-06),

9. 10788496 - MEK1 mutation conferring resistance to RAF and MEK inhibitors (2020-09-29),

10. 9880169 - MEK1 mutation conferring resistance to RAF and MEK inhibitors (2018-01-30),

11. 9629839 - C-RAF mutants that confer resistance to RAF inhibitors (2017-04-25),

12. 9370551 - Compositions and methods of treating head and neck cancer (2016-06-21),

13. 9279144 - Screening method for BRAF inhibitors (2016-03-08),

14. 9084781 - MEK mutations conferring resistance to MEK inhibitors (2015-07-21),

15. 8637246 - BRAF mutations conferring resistance to BRAF inhibitors (2014-01-28),

Title: Inventor Levi A. Garraway - Pioneering Innovations in Newton, MA

Introduction: Levi A. Garraway is a talented inventor based in Newton, MA, known for her groundbreaking contributions to the field of biotechnology and medical research.

Latest Patents: Levi A. Garraway holds several patents related to novel cancer therapies and precision medicine technologies, showcasing her commitment to advancing healthcare solutions.

Career Highlights: With a background in oncology and genetics, Levi A. Garraway has held key positions in renowned research institutions and biopharmaceutical companies, driving forward cutting-edge projects in the fight against cancer.

Collaborations: Throughout her career, Levi A. Garraway has collaborated with leading scientists, medical professionals, and industry experts to bring innovative ideas from the lab to the market, fostering a culture of collaboration and excellence.

Conclusion: Levi A. Garraway's dedication to pushing the boundaries of science and medicine has solidified her reputation as a visionary inventor, shaping the future of healthcare with her transformative innovations.